PharmGen Science, Inc. Q3 operating profit KRW 0.9 billion, down 32.2% from a year earlier; sales KRW 44.6 billion
AI summary · Not investment advice
Pharmgen Science sold KRW 44.6 billion in Q3 and earned KRW 0.9 billion from its main business, down 32.2% from a year earlier and 48.2% from the previous quarter.
Operating profit · 3 months
KRW 931.8 million
Key facts
- Revenue (3 months)
- KRW 44.6 billion
- Net income (3 months)
- KRW -2.3 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 41.5 billion
- Revenue (year to date)
- KRW 135.6 billion
- Operating profit (prior-year 3 months)
- KRW 1.4 billion
- Operating profit (year to date)
- KRW 4.5 billion
- Net income (prior-year 3 months)
- KRW -2.3 billionNet loss
- Net income (year to date)
- KRW -16.9 billionNet loss
Commentary
AI commentary · Not investment advice
What happened
Pharmgen Science filed its quarterly report with standalone results for the third quarter of 2026. Sales for the latest 3 months were KRW 44.59 billion. That is 7.4% more than the same 3 months a year earlier (KRW 41.51 billion). It is 6.5% less than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was KRW 931.8 million. That is 32.2% less than a year earlier (KRW 1.37 billion). It is 48.2% less than the previous quarter.
What changes for shareholders
Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 2.34 billion. A year earlier, the same 3 months showed a loss of KRW 2.28 billion.
For the year so far (January 1 to September 30), sales were KRW 135.63 billion. Operating profit was KRW 4.50 billion. Net income was a loss of KRW 16.91 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
P